ED STATES PATENT AND TRADEMARK OFFICE

In re Application

Application No.:

BYK, et al.

Examiner:

W. Alvarado

Art Unit:

1635

09/647,678

Filed:

October 2, 2000

Title: New Agents for Transferring Nucleic Acids, **Compositions Containing Them and Their Uses** I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 20, 2004
Date of Deposit

Bonnie Stein Signature

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. Two duplicate copies of this sheet are enclosed. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-4854 (908) 231-2626 **Telefax**

Aventis Docket No. USST98009AUS PCT

IN THE LINE TED STATES PATENT AND TRADEMARK OFFICE

In re Application of

BYK, et al

AU6 2 3 2004

W. Alvarado

rt Unit:

Examiner:

1635

Application No.:

09/647,678

Filed:

October 2, 2000

Title: New Agents for Transferring Nucleic Acids, Compositions Containing Them and

Their Uses

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 20, 2004

Date of Deposit

Bonnie Stein Banner Steen Signature

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

08/25/2004 RMEBRAHT 00000018 181982 09647678

1 1

01 FC:1806

180.00 DA

\leq	(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
		1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
		or a	notice of allowance under §1.311, whichever occurs first.
		(1)	The undersigned attorney certifies that each item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application not more than three months prior
			to the filing of this statement;
		(2)	The undersigned attorney certifies that no item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application or, to the knowledge of the
			undersigned attorney after making reasonable inquiry, was known to any
			individual designated in §1.56(c) more than three months prior to the filing of this
			statement; or
	\boxtimes	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
			authorized.

Respectfully submitted

William C. Coppora Reg. No. 41,686

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626
Aventis Decket No. LISST08000 AI

Please type a	nhus	cian	(+۱	inside	this hox	_

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number

	ute for form 1449B		MADES	Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/647,678 12-08-2000 BYK, et al		
				Filing Date			
				First Named Inventor			
0.7		. – .	,	Group Art Unit	1647		
	(use as mai	ny sheet	s as necessary)	Examiner Name	W. Alvarado		
Sheet	1	of	1	Attorney Docket Number	USST98009 - US - PCT		

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
		ALAM et al, Reporter Genes: Application to the Study of Mammalian Gene Transcription, Annal. Biochem, Vol. 188, 1990, pp 245-254					
		ALINO et al, Expression of Human alpha1-Antitrypsin in Mouse Afer in vivo Gene Transfer to Hepatocytes by Small Liposomes, Biochemical and Biophysical Research Communications, Vol. 204(3), 1994, pp 1023-1030					
·		BRIGHAM et al, Expression of Human Growth Hormone Fusion Genes in Cultured Lung Endothelial Cells and in the Lungs of Mice, American Journal of Respiratory Cell and Molecular Biology, Vol. 8, 1993, pp 209-213					
		CANONICO et al, Aerosol and Intravenous Transfection of Human alpha1-Antitrypsin Gene to Lungs of Rabbits, American Journal of Respiratory Cell and Molecular Biology, Vol. 10, 1994, pp 24-29					
		NABEL et al, Site-Specific Gene Expression in Vivo by Direct Gene Transfer into the Arterial Wall, Science, Vol. 249, 1990, pp 1285-1288					
		SORSCHER et al, Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer: A Phase I Trial of Safety and Efficacy in the Nasal Airway, Human Gene Therapy, Vol. 5, 1994, pp 1259-1277					
		WILSON et al, Hepatocyte-directed Gene Transfer in Vivo Leads to Transient Improvement of Hypercholesterolemia in Low Density Lipoprotein Receptor-deficient Rabbits, The Journal of Biological Chemistry, Vol. 267, No. 2, 1992, pp 963-967					
140		ZHU et al, Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice, Science, Vol. 261, 1993, pp 209-211					

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.